SNDX has been the subject of several recent research reports.
Syndax Pharmaceuticals (NASDAQ:SNDX) opened at 13.58 on Friday. They issued a "buy" rating on the stock. Finally, FBR & Co began coverage on Syndax Pharmaceuticals in a research report on Thursday, March 16th. They set an "outperform" rating on the stock. Nomura initiated coverage on Syndax Pharmaceuticals in a research note on Wednesday, March 1st. They set a buy rating and a $27.00 price target for the company. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company's stock. The recent change has given its price a -2.82% deficit over SMA 50 and -7.08% deficit over its 52-week high. The stock had a trading volume of 554,845 shares. (SNDX) has the trading volume of 4.27 Million shares with the average trading volume of 627440 shares.
Looking at the current price of the stock and the 52 week high and low, it suggests that the stock is likely to go Down in the future. The 200 SMA is considered so critically important a trend indicator that the event of the 50-day SMA crossing to the downside of the 200-day SMA is referred to as a death cross, signaling a serious bear market in a stock, index or other investment. (SNDX) now has a value of $13.58 while the company's 52 week low is at $6.31, the shares dropped to the 52 week low on 01/23/17. The company reported ($0.71) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.74) by $0.03. The company had revenue of $0.31 million for the quarter, compared to the consensus estimate of $0.31 million. Syndax Pharmaceuticals had a negative return on equity of 306.05% and a negative net margin of 3,388.98%. Syndax Pharmaceuticals Inc (NASDAQ:SNDX) has risen 6.00% since April 18, 2017 and is uptrending.
COPYRIGHT VIOLATION WARNING: This article was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this story on another publication, it was stolen and republished in violation of United States & global trademark & copyright laws. The correct version of this story can be accessed at https://www.chaffeybreeze.com/2017/05/17/syndax-pharmaceuticals-inc-sndx-downgraded-by-zacks-investment-research-to-hold.html. Point72 Asset Management L.P. bought a new stake in shares of Syndax Pharmaceuticals during the first quarter worth about $1,358,000.
If you look at the company's income statement over the past years, you will see that the company is constantly posting gross profit: In 2014, SNDX earned gross profit of 0, in 2015 0 gross profit, while in 2016 Syndax Pharmaceuticals, Inc. Sphera Funds Management LTD. purchased a new stake in Syndax Pharmaceuticals during the third quarter valued at $2,521,000. Going from the most negative analyst price target to above consensus is one thing. Alyeska Investment Group L.P. now owns 225,000 shares of the company's stock valued at $1,613,000 after buying an additional 56,228 shares during the last quarter.
COPYRIGHT VIOLATION NOTICE: "Syndax Pharmaceuticals (SNDX) Getting Somewhat Positive Press Coverage, Study Shows" was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. The stock price recently experienced a 5-day gain of 62.25% with 1.15 average true range (ATR).
Syndax is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies.